xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.23262, Wiley Online Library on [02/01/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

319

ICAR SINONASAL TUMORS

TABLE XXVI.3 Evidence surrounding sinonasal ENKTL treatment.

Clinical endpoints

Study

Year LOE Study design Study groups

Conclusion

He et al. 1898

1. OS 2. DSS

1. Nonnasal ENKTLs have shown improved OS over time 2. There has been no change in survival in nasal ENKTL 3. Univariate analysis showed lack of RT was associated with shorter OS/DSS, but this was not significant on multivariate analysis 1. CRT confers OS benefit compared to chemotherapy or RT alone for both early- and late-stage cohorts 2. Older age, paranasal sinus site, more comorbidities, and higher Ann Arbor stage predicted worseOS 3. RT and chemotherapy associated with improved OS 1. 2-year OS was 74% and 2-year PFSwas 70% 2. SMILE may offer reasonable control at the cost of significant toxicity

714 patients treated nationally for ENKTL

2021

4

Retrospective database study (SEER)

Lehrich

2021

4

Retrospective database review (NCDB)

785 patients with ENKTL

OS

et al. 1846

Gupta et al. 1847

1. OS 2. PFS

2018 4

Retrospective case series

16 patients with stage I or II disease treated withSMILE regimen and RT at 45–50Gy ENKTL treated with RT (median dose 50 Gy) with 40 105 patients with 215 patients treated at a single institution (all stage IE or IIE); 211 received CRT and four received RT. CHOP or CHOP-like regimen used in 175, l-asparaginase in 31 patients, and five received other chemotherapy regimen. Median RT dose was 55 Gy Five ENKTL patients treated at a single institution, with four patients undergoing combined CRT (unspecified regimen) patients receiving chemotherapy as well (unspecified regimen)

Wuet al. 1899

2017 4

Retrospective case series

Prognostic value of imaging characteristics

1. 5-year OS was 72.8% 2. PFS 65.2%

Niuet al. 1900

OS was higher for nasal than extra-nasal ENKTL (68.2 vs. 46%) at 5 years

1. OS 2. Risk factors

2016 4

Retrospective case series

for treatment failure

Steele et al. 1839

2016 4

Retrospective case series

OS

1. OS for ENKTL group was found tobe40% 2. Survival benefit was seen with CRT compared to chemotherapy alone

(Continues)